Department of Chemistry & Biochemistry, University of Missouri-St. Louis, St. Louis, MO 63121, USA.
J Inorg Biochem. 2011 Sep;105(9):1148-55. doi: 10.1016/j.jinorgbio.2011.05.021. Epub 2011 Jun 12.
Serum transferrin is the protein that transports ferric ion through the bloodstream and is thus a potential target for iron chelation therapy. However, the release of iron from transferrin to low-molecular-weight chelating agents is usually quite slow. Thus a better understanding of the mechanism for iron release is important to assist in the design of more effective agents for iron removal. This paper describes the effect of sulfonate anions on the rates of iron removal from C-terminal monoferric transferrin by acetohydroxamic acid, deferiprone, nitrilotriacetic acid (NTA), and diethylenetriaminepentaacetic acid at 25°C in 0.1M N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (Hepes) buffer at pH 7.4. These ligands remove iron via a combination of pathways that show saturation and first order dependence on the ligand concentration. The kinetic effects of the anions methanesulfonate, methylenedisulfonate, and ethylenedisulfonate were evaluated. All these anions increase the overall rates of iron release, presumably by binding to an allosteric anion binding site on the protein. The two disulfonates produce a larger acceleration in iron release than the monosulfonate. More detailed studies using methylenedisulfonate show that this anion accelerates the rate of iron release via the saturation pathway. The addition of methylenedisulfonate results in the appearance of a large saturation pathway for iron release by NTA, which otherwise removes iron by a simple first-order process. The sulfonate group was selected for these studies because it represents an anionic functional group that can be covalently linked to a therapeutic ligand to accelerate iron release in vivo. The current studies indicate that the binding of the sulfonates to the allosteric site on the protein is quite weak, so that one would not expect a significant acceleration in iron release at clinically relevant ligand concentrations.
血清转铁蛋白是一种在血液中运输三价铁离子的蛋白质,因此是铁螯合疗法的潜在靶标。然而,转铁蛋白向低分子量螯合剂释放铁通常非常缓慢。因此,更好地了解铁释放的机制对于协助设计更有效的铁去除剂非常重要。本文描述了在 25°C 下,在 0.1M N-(2-羟乙基)哌嗪-N'-(2-乙磺酸)(Hepes)缓冲液(pH 7.4)中,磺酸盐阴离子对乙二胺四乙酸(EDTA)、去铁酮、氮川三乙酸(NTA)和乙酰羟肟酸从 C 端单铁转铁蛋白中去除铁的速率的影响。这些配体通过显示对配体浓度的饱和和一级依赖的组合途径去除铁。评估了甲磺酸盐、甲叉二磺酸盐和乙叉二磺酸盐阴离子的动力学效应。所有这些阴离子都增加了铁释放的总体速率,可能是通过与蛋白质上的变构阴离子结合位点结合。两种二磺酸盐比单磺酸盐产生更大的铁释放加速作用。使用甲叉二磺酸盐进行的更详细研究表明,该阴离子通过饱和途径加速铁释放速率。添加甲叉二磺酸盐会导致 NTA 的铁释放出现大的饱和途径,否则 NTA 通过简单的一级过程去除铁。选择磺酸盐进行这些研究是因为它代表了一种阴离子官能团,可以共价连接到治疗性配体上,以加速体内铁释放。目前的研究表明,磺酸盐与蛋白质变构位点的结合非常弱,因此在临床相关的配体浓度下,不会预期铁释放会有明显的加速。